Literature DB >> 22699519

Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples.

Gerard J Nuovo1, Michela Garofalo, Nicola Valeri, Vicki Roulstone, Stefano Volinia, David E Cohn, Mitch Phelps, Kevin J Harrington, Richard Vile, Alan Melcher, Evanthia Galanis, Sarah Sehl, Rob Adair, Karen Scott, Ailsa Rose, Giles Toogood, Matthew C Coffey.   

Abstract

We analyzed the in situ molecular correlates of infection from cancer patients treated with reovirus. Melanoma, colorectal, and ovarian cancer samples from such patients showed variable infection of the cancer cells but not the intermingled benign cells. RT in situ PCR showed most cancer cells contained the viral genome with threefold less having productive viral infection as documented by either tubulin or reoviral protein co-expression. Productive infection in the cancer cells was strongly correlated with co-expression of p38 and caspase-3 as well as apoptosis-related death (P<0.001). The cancer cell apoptotic death was due to a marked viral-induced inhibition of microRNA-let-7d that, in turn, upregulated caspase-3 activity. In summary, reovirus shows a striking tropism to cancer cells in clinical samples. A rate-limiting factor of reovirus-induced cancer cell death is productive viral infection that operates via the marked reduction of microRNA-let-7d and concomitant elevated caspase-3 expression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22699519      PMCID: PMC4275064          DOI: 10.1038/modpathol.2012.95

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  26 in total

1.  Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.

Authors:  Timothy Kottke; Geoff Hall; Jose Pulido; Rosa Maria Diaz; Jill Thompson; Heung Chong; Peter Selby; Matt Coffey; Hardev Pandha; John Chester; Alan Melcher; Kevin Harrington; Richard Vile
Journal:  J Clin Invest       Date:  2010-04-01       Impact factor: 14.808

2.  Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.

Authors:  Timothy Kottke; Jill Thompson; Rosa Maria Diaz; Jose Pulido; Candice Willmon; Matt Coffey; Peter Selby; Alan Melcher; Kevin Harrington; Richard G Vile
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

3.  Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma.

Authors:  Hardev S Pandha; Lucy Heinemann; Guy R Simpson; Alan Melcher; Robin Prestwich; Fiona Errington; Matt Coffey; Kevin J Harrington; Richard Morgan
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

4.  Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.

Authors:  Shizuko Sei; Jodie K Mussio; Quan-en Yang; Kunio Nagashima; Ralph E Parchment; Matthew C Coffey; Robert H Shoemaker; Joseph E Tomaszewski
Journal:  Mol Cancer       Date:  2009-07-14       Impact factor: 27.401

5.  let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression.

Authors:  Jérôme Torrisani; Barbara Bournet; Maël Chalret du Rieu; Michèle Bouisson; Anny Souque; Jean Escourrou; Louis Buscail; Pierre Cordelier
Journal:  Hum Gene Ther       Date:  2009-08       Impact factor: 5.695

6.  Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus.

Authors:  Robin J Prestwich; Fiona Errington; Lynette P Steele; Elizabeth J Ilett; Ruth S M Morgan; Kevin J Harrington; Hardev S Pandha; Peter J Selby; Richard G Vile; Alan A Melcher
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

Review 7.  Reovirus therapy in cancer: has the orphan virus found a home?

Authors:  Timothy A Yap; Andre Brunetto; Hardev Pandha; Kevin Harrington; Johann S Debono
Journal:  Expert Opin Investig Drugs       Date:  2008-12       Impact factor: 6.206

8.  CUG2, a novel oncogene confers reoviral replication through Ras and p38 signaling pathway.

Authors:  E-H Park; E H Park; I-R Cho; R Srisuttee; H-J Min; M-J Oh; Y-J Jeong; B H Jhun; R N Johnston; S Lee; S S Koh; Y-H Chung
Journal:  Cancer Gene Ther       Date:  2010-01-15       Impact factor: 5.987

Review 9.  The utility of in situ--based methodologies including in situ polymerase chain reaction for the diagnosis and study of viral infections.

Authors:  Gerard J Nuovo
Journal:  Hum Pathol       Date:  2007-08       Impact factor: 3.466

10.  Reovirus decreases azoxymethane-induced aberrant crypt foci and colon cancer in a rodent model.

Authors:  T Alain; J F Wong; R Endersby; S J Urbanski; P W Lee; D A Muruve; R N Johnston; P A Forsyth; P L Beck
Journal:  Cancer Gene Ther       Date:  2007-07-13       Impact factor: 5.987

View more
  25 in total

1.  Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions.

Authors:  Louisa Mezache; Cynthia Magro; Craig Hofmeister; Flavia Pichiorri; Douglas Sborov; Gerard J Nuovo
Journal:  Appl Immunohistochem Mol Morphol       Date:  2017-02

2.  Let-7d microRNA Attenuates 6-OHDA-Induced Injury by Targeting Caspase-3 in MN9D Cells.

Authors:  Li Li; Hui Liu; Haijing Song; Yingsong Qin; Ying Wang; Ming Xu; Chaoxia Liu; Jin Gao; Shen Sun
Journal:  J Mol Neurosci       Date:  2017-10-29       Impact factor: 3.444

3.  Attenuation of miR-17∼92 Cluster in Bronchopulmonary Dysplasia.

Authors:  Lynette K Rogers; Mary Robbins; Duaa Dakhlallah; Zhaogang Yang; L James Lee; Madison Mikhail; Gerard Nuovo; Gloria S Pryhuber; Gerald McGwin; Clay B Marsh; Trent E Tipple
Journal:  Ann Am Thorac Soc       Date:  2015-10

4.  Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  David E Cohn; Michael W Sill; Joan L Walker; David O'Malley; Christa I Nagel; Teresa L Rutledge; William Bradley; Debra L Richardson; Katherine M Moxley; Carol Aghajanian
Journal:  Gynecol Oncol       Date:  2017-07-27       Impact factor: 5.482

5.  Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model.

Authors:  Chandini M Thirukkumaran; Zhong Qiao Shi; Gerard J Nuovo; Joanne Luider; Karen A Kopciuk; Yuan Dong; Ahmed A Mostafa; Satbir Thakur; Kathy Gratton; Ailian Yang; Alex C Chin; Matt C Coffey; Victor H Jimenez-Zepeda; Douglas Stewart; Marta Chesi; P Leif Bergsagel; Don Morris
Journal:  Blood Adv       Date:  2019-03-12

6.  Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Authors:  Adel Samson; Karen J Scott; David Taggart; Emma J West; Erica Wilson; Gerard J Nuovo; Simon Thomson; Robert Corns; Ryan K Mathew; Martin J Fuller; Timothy J Kottke; Jill M Thompson; Elizabeth J Ilett; Julia V Cockle; Philip van Hille; Gnanamurthy Sivakumar; Euan S Polson; Samantha J Turnbull; Elizabeth S Appleton; Gemma Migneco; Ailsa S Rose; Matthew C Coffey; Deborah A Beirne; Fiona J Collinson; Christy Ralph; D Alan Anthoney; Christopher J Twelves; Andrew J Furness; Sergio A Quezada; Heiko Wurdak; Fiona Errington-Mais; Hardev Pandha; Kevin J Harrington; Peter J Selby; Richard G Vile; Stephen D Griffin; Lucy F Stead; Susan C Short; Alan A Melcher
Journal:  Sci Transl Med       Date:  2018-01-03       Impact factor: 17.956

7.  miR-29b supplementation decreases expression of matrix proteins and improves alveolarization in mice exposed to maternal inflammation and neonatal hyperoxia.

Authors:  Shaheen Durrani-Kolarik; Caylie A Pool; Ashley Gray; Kathryn M Heyob; Mary J Cismowski; Gloria Pryhuber; L James Lee; Zhaogang Yang; Trent E Tipple; Lynette K Rogers
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-05-04       Impact factor: 5.464

8.  ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer.

Authors:  Marco Napoli; Avinashnarayan Venkatanarayan; Payal Raulji; Brooke A Meyers; William Norton; Lingegowda S Mangala; Anil K Sood; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Harina Vin; Madeleine Duvic; Michael B Tetzlaff; Jonathan L Curry; Alain H Rook; Hussein A Abbas; Cristian Coarfa; Preethi H Gunaratne; Kenneth Y Tsai; Elsa R Flores
Journal:  Cancer Cell       Date:  2016-06-13       Impact factor: 31.743

Review 9.  Exosomal miRNAs: novel players in viral infection.

Authors:  Javid Sadri Nahand; Maryam Mahjoubin-Tehran; Mohsen Moghoofei; Mohammad Hossein Pourhanifeh; Hamid Reza Mirzaei; Zatollah Asemi; Alireza Khatami; Farah Bokharaei-Salim; Hamed Mirzaei; Michael R Hamblin
Journal:  Epigenomics       Date:  2020-02-25       Impact factor: 4.778

10.  Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers.

Authors:  Louisa Mezache; Bernard Paniccia; Angelique Nyinawabera; Gerard J Nuovo
Journal:  Mod Pathol       Date:  2015-09-25       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.